Display options
Cite
Tripathy S, Vinokour E, McMahon KM, et al. High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis. Part Part Syst Charact. 2014;31(11):1141-1150doi: 10.1002/ppsc.201400036.
Tripathy, S., Vinokour, E., McMahon, K. M., Volpert, O. V., & Thaxton, C. S. (2014). High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis. Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems, 31(11), 1141-1150. https://doi.org/10.1002/ppsc.201400036
Tripathy, Sushant, et al. "High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis." Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems vol. 31,11 (2014): 1141-1150. doi: https://doi.org/10.1002/ppsc.201400036
Tripathy S, Vinokour E, McMahon KM, Volpert OV, Thaxton CS. High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis. Part Part Syst Charact. 2014 Nov 01;31(11):1141-1150. doi: 10.1002/ppsc.201400036. PMID: 25400330; PMCID: PMC4228967.
Copy Download .nbib Format: NLM
Share it on

Part Part Syst Charact. 2014 Nov 01;31(11):1141-1150. doi: 10.1002/ppsc.201400036.

High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis.

Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems

Sushant Tripathy, Elena Vinokour, Kaylin M McMahon, Olga V Volpert, C Shad Thaxton

Affiliations

  1. Northwestern University, Feinberg School of Medicine, Department of Urology, 303 East Chicago Avenue, Tarry 16-703, Chicago, Illinois 60611, United States ; Northwestern University, Institute for BioNanotechnology and Medicine (IBNAM), 303 East Superior Avenue, 11th Floor, Chicago, Illinois 60611, United States ; Driskill Graduate Program, Northwestern University, Chicago, Illinois 60611, United States.
  2. Northwestern University, Feinberg School of Medicine, Department of Urology, 303 East Chicago Avenue, Tarry 16-703, Chicago, Illinois 60611, United States.
  3. Northwestern University, Feinberg School of Medicine, Department of Urology, 303 East Chicago Avenue, Tarry 16-703, Chicago, Illinois 60611, United States ; Northwestern University, Robert H. Lurie Comprehensive Cancer Center, 303 East Superior Avenue, Chicago, Illinois 60611, United States.
  4. Northwestern University, Feinberg School of Medicine, Department of Urology, 303 East Chicago Avenue, Tarry 16-703, Chicago, Illinois 60611, United States ; Northwestern University, Robert H. Lurie Comprehensive Cancer Center, 303 East Superior Avenue, Chicago, Illinois 60611, United States ; Northwestern University, Institute for BioNanotechnology and Medicine (IBNAM), 303 East Superior Avenue, 11th Floor, Chicago, Illinois 60611, United States ; Northwestern University, International Institute for Nanotechnology, 2145 Sheridan Road, Evanston, Illinois 60208, United States.

PMID: 25400330 PMCID: PMC4228967 DOI: 10.1002/ppsc.201400036

Abstract

Systemic delivery of therapeutic nucleic acids to target cells and tissues outside of the liver remains a major challenge. We synthesized a biomimetic high density lipoprotein nanoparticle (HDL NP) for delivery of a cholesteryl modified therapeutic nucleic acid (RNAi) to vascular endothelial cells, a cell type naturally targeted by HDL. HDL NPs adsorb cholesteryl modified oligonucleotides and protect them from nuclease degradation. As proof of principle, we delivered RNAi targeting vascular endothelial growth factor receptor 2 (

Keywords: Angiogenesis; HDL; RNAi; Tumor; VEGFR2

References

  1. Nat Cell Biol. 2011 Apr;13(4):423-33 - PubMed
  2. Ann N Y Acad Sci. 2011 Jul;1229:E1-7 - PubMed
  3. Oncologist. 2004;9 Suppl 1:2-10 - PubMed
  4. J Drug Target. 2008 Jul;16(6):502-8 - PubMed
  5. Circ Res. 2009 May 22;104(10):1142-50 - PubMed
  6. Neoplasia. 2011 Apr;13(4):309-19 - PubMed
  7. Cancer. 2012 Jun 1;118(11):2780-6 - PubMed
  8. Nat Rev Genet. 2011 May;12(5):329-40 - PubMed
  9. Cancer Res. 2000 Feb 15;60(4):970-5 - PubMed
  10. Int J Mol Med. 2005 Oct;16(4):717-22 - PubMed
  11. Clin Cancer Res. 2012 Jan 15;18(2):454-64 - PubMed
  12. Front Oncol. 2012 Feb 15;2:13 - PubMed
  13. J Cell Biol. 2003 Jun 23;161(6):1163-77 - PubMed
  14. Int J Mol Med. 2013 Oct;32(4):763-7 - PubMed
  15. Science. 1996 Jan 26;271(5248):518-20 - PubMed
  16. Cancer Res. 2000 Apr 15;60(8):2178-89 - PubMed
  17. Curr Clin Pharmacol. 2008 May;3(2):132-43 - PubMed
  18. Endocr Rev. 2003 Jun;24(3):357-87 - PubMed
  19. Cancer Res. 1996 Aug 1;56(15):3540-5 - PubMed
  20. J Biol Chem. 2009 Feb 27;284(9):5797-806 - PubMed
  21. Nat Clin Pract Oncol. 2007 Aug;4(8):470-9 - PubMed
  22. Br J Cancer. 2004 Oct 4;91(7):1391-8 - PubMed
  23. Curr Opin Investig Drugs. 2008 Dec;9(12):1287-95 - PubMed
  24. Cancer Cell. 2007 Jan;11(1):83-95 - PubMed
  25. Mol Cancer Ther. 2009 Jul;8(7):1761-71 - PubMed
  26. Am J Ophthalmol. 2009 Nov;148(5):647-56 - PubMed
  27. Cancer Lett. 2013 Sep 28;338(2):219-28 - PubMed
  28. J Drug Target. 2010 Jan;18(1):53-8 - PubMed
  29. Nanomedicine (Lond). 2014 Jan;9(1):105-20 - PubMed
  30. Target Oncol. 2011 Dec;6(4):197-202 - PubMed
  31. Curr Treat Options Oncol. 2007 Feb;8(1):15-27 - PubMed
  32. Nanomedicine (Lond). 2012 Dec;7(12):1813-25 - PubMed
  33. Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 - PubMed
  34. Small. 2010 Feb 5;6(3):430-7 - PubMed
  35. Nano Lett. 2011 Mar 9;11(3):1208-14 - PubMed
  36. Can J Cardiol. 2006 Feb;22 Suppl B:35B-40B - PubMed
  37. Nat Biotechnol. 2007 Oct;25(10):1149-57 - PubMed
  38. Eur J Cancer. 2010 Jan;46(2):439-48 - PubMed
  39. Trends Cardiovasc Med. 2013 May;23(4):104-13 - PubMed

Publication Types

Grant support